ClinicalTrials.gg

Program

QL2107

Also written as “QLS5132; QL1706; QL2107”, “QLS5132; QL1706; QL2107; Carboplatin; Cisplatin; Oxaliplatin” and “QLC1101+QL2107”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasms, led by Qilu Pharmaceutical.

Furthest: phase 3, since Dec 23, 20245 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical55 open or runningphase 3since Dec 23, 2024Nov 29, 2023Dec 2026phase 3 · NCT06754644

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 29, 2023First study: phase 1 study in NeoplasmsFirst studyNCT06173011 · 168 planned · China
  2. Dec 23, 2024Phase 3 study in NSCLCNCT06754644 · 808 planned · China
  3. Apr 22, 2025Phase 2 study in Solid TumorNCT06949761 · 240 planned
  4. Aug 31, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07162883 · 146 enrolled · Bosnia and Herzegovina, China, Georgia and more
  5. Mar 1, 2026Phase 2 study in Stomach NeoplasmsNCT07453394 · 626 planned

Ahead

  1. Dec 2026Primary completion: phase 3 study in NSCLCNCT06754644
  2. Dec 31, 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07162883
  3. Apr 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT07453394

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07453394Stomach Neoplasms2Not yet recruitingApr 2027626
NCT07162883Carcinoma, Non-Small-Cell Lung · Bosnia and Herzegovina, China, Georgia and more3Active, not recruitingDec 31, 2026146
NCT06949761Solid Tumor2Not yet recruitingSep 2026240
NCT06754644NSCLC · China3RecruitingDec 2026808
NCT06173011Neoplasms · China1RecruitingJul 2024168

How it is read

Names in the registry

  • “QL2107”, 3 entries
  • “QLS5132; QL1706; QL2107”, 1 entry
  • “QLS5132; QL1706; QL2107; Carboplatin; Cisplatin; Oxaliplatin”, 1 entry
  • “QLC1101+QL2107”, 1 entry

Codes read as this program: QL2107.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.